36
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4624 |
PGD2-IN-1
PGD2-inhibitor |
Prostaglandin Receptor | GPCR/G Protein; Immunology/Inflammation |
PGD2-IN-1 (PGD2-inhibitor) 是 一种有效的DP 受体拮抗剂(IC50 : 0.3 nM),是一种可以抑制前列腺素D2 (PGD2)信号传导的化合物。PGD2-IN-1 专门针对和调节PGD2受体或参与PGD2合成或代谢的酶的活性。 | |||
T1804 |
HPGDS inhibitor 1
HPGDS-inhibitor-1 |
PGE Synthase | Immunology/Inflammation |
HPGDS inhibitor 1 是口服具有活性的HPGDS 选择性抑制剂,在酶和细胞分析中的IC50值分别为 0.6 nM 和 32 nM,但对 L-PGDS、mPGES、COX-1、COX-2 、5-LOX 无抑制作用。 | |||
T17232 |
Vidupiprant
AMG 853 |
Prostaglandin Receptor | GPCR/G Protein; Immunology/Inflammation |
Vidupiprant (AMG 853) 是一种有效的 CRTH2 和前列腺素 D 受体双重拮抗剂,在人源血浆中的 IC50 分别为 8 nM 和 35 nM。 Vidupiprant 可用于治疗哮喘的研究。 | |||
T37264 |
15(R)-15-methyl Prostaglandin D2
15(R)15methyl PGD2 |
GPR | Endocrinology/Hormones; GPCR/G Protein |
15(R)-15-methyl Prostaglandin D2 (15(R)15methyl PGD2) 是一种 PGD2 合成类似物,也是一种具有选择性和强效性的 CRTH2/DP2 受体激动剂,可调节嗜酸性粒细胞 CD11b 表达、肌动蛋白聚合和趋化。 | |||
T3520 |
Setipiprant
KYTH-105,塞替匹仑,ACT-129968 |
GPR; Prostaglandin Receptor | Endocrinology/Hormones; GPCR/G Protein; Immunology/Inflammation |
Setipiprant (ACT-129968) 是一种口服的选择性 CRTH2 拮抗剂,IC50为6.0 nM。 | |||
T16280 |
Nedocromil
FPL 59002,尼多克罗 |
Leukotriene Receptor; Prostaglandin Receptor; Histamine Receptor | GPCR/G Protein; Immunology/Inflammation; Neuroscience |
Nedocromil (FPL 59002) 对多种介质的作用或形成有抑制作用,包括组胺,前列腺素 D2和白三烯 C4。 | |||
T15712 |
Laropiprant
MK-0524 |
Prostaglandin Receptor | GPCR/G Protein; Immunology/Inflammation |
Laropiprant (MK-0524) 是 DP receptor 的选择性拮抗剂,Ki 为 0.57 nM,对 TP 受体的 Ki 为 2.95 nM。 | |||
T14565 |
BI-671800
AP-761,Cmpd A |
GPR; Prostaglandin Receptor | Endocrinology/Hormones; GPCR/G Protein; Immunology/Inflammation |
BI-671800 (AP-761) 是高特异性的前列腺素 D2 受体拮抗剂,对哮喘有研究潜力,对人和小鼠 CRTH2 转染细胞中 PGD2 结合 CRTH2 的 IC50值分别为 4.5 和 3.7 nM。 | |||
T7652 |
AM211
AM211 free acid |
Prostaglandin Receptor | GPCR/G Protein; Immunology/Inflammation |
AM211 (AM211 free acid) 是可口服的选择性前列腺素受体拮抗剂,对人、小鼠、豚鼠和大鼠的 DP2 的IC50值分别为 4.9、7.8、4.9 和 10.4 nM。 | |||
T2690 |
Tranilast
曲尼司特,MK 341,SB 252218 |
RAAS; Prostaglandin Receptor | Endocrinology/Hormones; GPCR/G Protein; Immunology/Inflammation |
Tranilast (SB 252218) 是一种抗过敏药物,可抑制炎症细胞释放脂质介质和细胞因子,抑制前列腺素 D2 (PGD2)产生,IC50为 0.1 mM。它拮抗血管紧张素 II 并抑制其在血管平滑肌细胞中的生物学作用,具有抗炎和免疫调节作用。 | |||
T1866 |
AT-56
|
Others; PGE Synthase | Immunology/Inflammation; Others |
AT56 是口服有活性的脂钙蛋白型前列腺素 D 合酶 (L-PGDS) 选择性抑制剂,其IC50=95 μM,Ki=75 μM。它能够特异性地抑制L-PGDS 催化的 PGD2介导的嗜睡或疼痛反应。 | |||
T2396 |
Ramatroban
BAY u3405,雷马曲班 |
GPR; Prostaglandin Receptor; PPAR | DNA Damage/DNA Repair; Endocrinology/Hormones; GPCR/G Protein; Immunology/Inflammation; Metabolism |
Ramatroban (BAY u3405) 是一种血栓素 A(2) (TxA(2)) 拮抗剂,IC50为 14 nM。它还通过抑制PGD2结合从而拮抗CRTH2,IC50为113 nM。它用于治疗过敏性鼻炎,可用于治疗哮喘的研究。 | |||
T2664 |
Timapiprant
OC000459 |
GPR; Prostaglandin Receptor | Endocrinology/Hormones; GPCR/G Protein; Immunology/Inflammation |
Timapiprant (OC000459) 是一种有效的选择性 D 前列腺素受体 2(DP2) 拮抗剂,IC50为 13 nM。它抑制肥大细胞激活 Th2 淋巴细胞和嗜酸性粒细胞,有效地置换来自人重组 DP2、大鼠重组 DP2 和人天然 DP2 的 [3H] PGD2。 | |||
T7359 |
CAY10471 Racemate
TM30089 Racemate,3-[[(4-氟苯基)磺酰基]甲基氨基]-1,2,3,4-四氢-9H-咔唑-9-乙酸 |
GPR; Prostaglandin Receptor | Endocrinology/Hormones; GPCR/G Protein; Immunology/Inflammation |
CAY10471 Racemate (TM30089 Racemate) 是一种高选择性的 CRTH2/DP 2 受体拮抗剂,对 hCRTH2 的Ki 值为 0.6 nM,对其选择性远高于人血栓素 A2 受体 TP 或 PGD2 受体 DP。它对大小鼠的同源 CRTH2 也具有拮抗作用。 | |||
T13855 |
Quinotolast sodium
FR71021 |
Others | Others |
Quinotolast sodium inhibits histamine, LTC4 and PGD2 release in a concentration-dependent manner in the concentration range of 1-100 μg/mL. | |||
T69967 |
Laropiprant analog
|
||
Laropiprant analog is an antagonist of the prostaglandin PGD2 receptor DP1. | |||
T38257 |
PGDM
|
||
Prostaglandin D2 (PGD2) plays a pharmacological role in allergic and asthmatic anaphylaxis, normal physiological sleep and lowering of body temperature, as well as inhibits platelet aggregation and relaxes vascular smooth muscle. PGDM is a major urinary metabolite of PGD2 with a unique lower sidechain that readily undergoes reversible cyclization. It is used as a biomarker to assess endogenous production of PGD2. | |||
T36153 |
15(S)-15-methyl Prostaglandin D2
15(S)-15-methyl Prostaglandin D2 |
||
15(S)-15-methyl Prostaglandin D2 (15(S)-15-methyl PGD2) is a metabolically stable synthetic analog of PGD2 . In contrast to PGD2, 15(S)-15-methyl PGD2 induces vasoconstriction and increases systemic blood pressure with much reduced inhibitory activity on ADP-induced platelet aggregation. It also exhibits strong antifertility activity in hamsters (200-fold more potent than PGD2). | |||
T36545 |
Prostaglandin D2 methyl ester
Prostaglandin D2 methyl ester |
||
Prostaglandin D2 (PGD2) is the major eicosanoid product of mast cells and is produced in large quantities by hematopoietic PGD synthase during allergic and asthmatic anaphylaxis. It causes vasodilation, flushing, hypotension, and is an inhibitor of platelet aggregation. Prostaglandin D2 methyl ester (PGD2 methyl ester) is a more lipid-soluble, cell-permeable prodrug form of PGD2. It binds to the human and mouse PGD2 receptors (DP1 and CRTH2/DP2) with 5-10 fold lower affinity than PGD2. | |||
T36213 |
16,16-dimethyl Prostaglandin D2
16,16-dimethyl Prostaglandin D2 |
||
16,16-dimethyl PGD2 is a metabolically stable synthetic analog of PGD2. It enhances ADP-induced human platelet aggregation and increases systemic blood pressure in rats. | |||
T38365 |
CAY10597
|
||
The biological effects of prostaglandin D2 (PGD2) are transduced by at least two 7-transmembrane G protein-coupled receptors, designated DP1 and CRTH2/DP2. In humans, CRTH2/DP2 is expressed on Th2 cells, eosinophils, and basophils where it mediates the chemotactic activity of PGD2. CAY10597, as a racemic mixture, is a potent CRTH2/DP2 receptor antagonist that binds to the human receptor with a Ki value of 37 nM. The R enantiomer is slightly more potent exhibiting Ki values of 23 and 22 nM at the... | |||
T38306 |
tetranor-PGDM
|
||
Prostaglandin D2 is synthesized by hematopoietic-type PGD-synthase (H-PGDS) in mast cells and is released in large quantities during allergic and asthmatic anaphylaxis. PGD2 is also produced in the brain by lipocalin-PGD-synthase also known as β-trace. In the brain, PGD2 produces normal physiological sleep and lowering of body temperature. Further pharmacological actions include inhibition of platelet aggregation and relaxation of vascular smooth muscle. tetranor-PGDM is a major metabolite of PG... | |||
T38389 |
Prostaglandin D2 Ethanolamide
Prostaglandin D2 Ethanolamide |
||
Prostaglandin D2 ethanolamide (PGD2-EA) is a bioactive lipid produced by the sequential metabolism of anandamide (arachidonoyl ethanolamide) by cyclooxygenase (COX) enzymes, in particular by COX-2, and PGD synthase. The biosynthesis of PGD2-EA from anandamide can also be increased when anandamide metabolism is diminished by deletion of fatty acid amide hydrolase. PGD2-EA is inactive against recombinant prostanoid receptors, including the D prostanoid receptor. It increases the frequency of minia... | |||
T15503 |
HQL-79
|
Others | Others |
HQL-79 is a selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor. It inhibits the synthesis of PGD2 and acts as an anti-allergic agent (Kd: 0.8 μM and IC50: 6 μM). It also shows no obvious effect on COX-1, COX-2, m-P | |||
T21869 |
BW A868C
|
||
BW A868C 是一种乙内酰脲化合物,是 BW245C 结构类似物。BW A868C 是一种选择性强的前列腺素 D2 (PGD2) 竞争性拮抗剂。BW A868C 对其他前列腺素受体 (IP、EP1、EP2、TP 和 FP) 没有影响。 | |||
T17099 |
Timapiprant sodium
OC000459 sodium |
Others | Others |
Timapiprant sodium inhibits mast cell activation of Th2 lymphocytes and eosinophils. Timapiprant sodium is a potent and selective D prostanoid receptor 2 antagonist. Timapiprant sodium potently displaces [3H] PGD2 from human recombinant DP2 (Ki=13 nM), ra | |||
T38113 |
AL 6598
|
||
Elevated intraocular pressure (IOP) is an important risk factor in developing glaucoma. Certain prostaglandins such as PGF2α and PGD2, have been shown to reduce IOP. AL 6598 is the isopropyl ester prodrug of AL 6556, a PGD2 receptor agonist that binds to DP receptors with a Ki value of 3.2 μM and demonstrates an EC50 value of 0.80 μM in an in vitro functional assay. Designed to enhance corneal absorption, AL 6598 produces a maximum 53% drop in IOP of the ocular hypertensive monkey with a 1 μg do... | |||
T73782 |
Prostaglandin J2
|
||
Prostaglandin J2 (PGJ2) 是前列腺素 D2 (PGD2) 的一种内源性代谢物,是一种有效的 PGD2 受体 (DP) 激动剂,对 hDP 和 hCRTH2 的 Ki 分别为 0.9 nM 和 6.6 nM。Prostaglandin J2 刺激细胞内环 AMP 的产生,EC50值为 1.2 nM。Prostaglandin J2 诱导氧化应激和神经细胞凋亡。Prostaglandin J2 诱导泛素化 (Ub) 蛋白的积累/聚集。Prostaglandin J2 具有高度神经毒性,可导致许多神经退行性疾病,包括阿尔茨海默病 (AD) 和帕金森病 (PD)。 | |||
T37506 |
MCTR2
MCTR2 |
||
Maresin conjugates in tissue regeneration 2 (MCTR2) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid in macrophages at the site of inflammation. DHA is oxidized to maresin 1 , which is converted to MCTR1 by glutathione S-transferase Mu 4 or leukotriene C4 synthase then to MCTR2 by γ-glutamyl transferase. MCTR2 accelerates tissue regeneration in planaria (1 and 100 nM). Pretreatment with MCTR2 prior to E. coli administration reduces neutrophil infiltration, shor... | |||
T35811 |
CAY10410
|
||
CAY10410 is an analog of prostaglandin D2/prostaglandin J2 (PGD2/PGJ2) with structural modifications intended to give it PPARγ ligand activity and resistance to metabolism. 15-deoxy-δ12,14-PGJ2 has been shown to be a potent ligand for PPARγ. Metabolism of the cyclopentenone prostaglandins PGA2, PGJ2, and δ12-PGJ2 occurs via glutathione addition across the α,β unsaturated enone. CAY10410 was designed as an analog of the PPARγ-binding prostaglandins which could not undergo this conjugation reactio... | |||
T41267 |
PROTAC(H-PGDS)-7
|
||
PROTAC(H-PGDS)-7 是一种有选择性的、有效的小分子造血前列腺素 D 合酶 (H-PGDS)PROTAC 降解剂,在 KU812细胞中展现出降解活性,DC50为 17.3 pM。PROTAC(H-PGDS)-7是一种类药化合物,能有效抑制前列腺素 D2 (PGD2)的产生,抑制炎症因子重生作用。PROTAC(H-PGDS)-7是治疗 DMD 和其他H-PGDS 相关疾病的候选化合物。 | |||
T37257 |
13,14-dihydro-15-keto Prostaglandin D1
13,14-dihydro-15-keto Prostaglandin D1 |
||
Prostaglandin D1 (PGD1) is the theoretical D-series metabolite of dihomo-γ-linolenic acid (DGLA), but to date it has not been isolated as a natural product. It is an inhibitor of ADP-induced platelet aggregation in humans with an IC50 value of 320 ng/ml, about 1/10 as potent as PGD2. 13,14-dihydro-15-keto Prostaglandin D1 (13,14-dihydro-15-keto PGD1) is the theoretical metabolite of PGD1 via the 15-hydroxy PG dehydrogenase metabolic pathway. No biological studies for this compound have been repo... | |||
T37300 |
PCTR1
PCTR1 |
||
Protectin conjugates in tissue regeneration 1 (PCTR1) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid . DHA is oxidized to 16S,17S-epoxy-protectin, which is then converted to PCTR1 by glutathione S-transferase. PCTR1 levels increase during resolution of acute microbial-induced peritonitis in mice. PCTR1 (30 ng, i.p.) administration 12 hours post-infection increases macrophage numbers and activity and shortens the resolution phase of inflammation by 57%. It als... | |||
T37275 |
2,3-dinor-11β-Prostaglandin F2α
2,3-dinor-11β-Prostaglandin F2α |
||
2,3-dinor-11β-Prostaglandin F2α (2,3-dinor-11β-PGF2α) was recovered from the urine of both normal monkeys and humans when infused with radiolabeled PGD2, where it represented approximately 1% and 4% of the infused radiolabeled dose, respectively. 2,3-dinor-11β-PGF2α has also been recovered from the urine of mastocytosis patients, where it is excreted in large amounts. In human asthmatic patients, 2,3-dinor-11β-PGF2α represents about 40% (as determined by GC/MS) of the immunoreactive 11β-PGF2α wh... | |||
T37507 |
MCTR3
MCTR3 |
||
Maresin conjugates in tissue regeneration 3 (MCTR3) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid in macrophages. DHA is oxidized to maresin 1 , which is converted to MCTR1 by glutathione S-transferase Mu 4 or leukotriene C4 synthase, then to MCTR2 by γ-glutamyl transferase, and to MCTR3 by dipeptidase. MCTR3 accelerates tissue regeneration in planaria (1 and 100 nM) approximately as potently as MCTR2 and more potently than MCTR1. Pretreatment with MCTR3 pri... | |||
T23472 |
Tranilast Sodium
|
Others | Others |
Tranilast Sodium has been used for the treatment of bronchial asthma. Tranilast is also used to autoimmune diseases, atopic and fibrotic pat. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T13831 |
Prostaglandin D2
PGD2 |
Endogenous Metabolite | Metabolism |
Prostaglandin D2 (PGD2) (PGD2) 是哺乳动物大脑中主要产生的前列腺素之一,为最有效的内源性睡眠促进剂之一,并通过抑制炎症发挥保护作用。 |